• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

    11/14/24 4:27:32 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BLUE alert in real time by email
    SC 13G/A 1 fp0090935-7_sc13ga.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (AMENDMENT NO. 1)*

     

    bluebird bio, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

     

    (Title of Class of Securities)

     

    09609G100

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [x]Rule 13d-1(b)
    [  ]Rule 13d-1(c)
    [  ]Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP NO. 09609G100

    13G Page 2 of 5 Pages

     

    1

    NAMES OF REPORTING PERSONS S.S. OR
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

     

    Granahan Investment Management LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a) [  ]

    (b) [  ]

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Massachusetts

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    0

     
    6

    SHARED VOTING POWER

     

    None

     
    7

    SOLE DISPOSITIVE POWER

     

    0

     
    8

    SHARED DISPOSITIVE POWER

     

    None

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

    [  ]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.00%

     
    12

    TYPE OF REPORTING PERSON

     

    IA

     

     

     

    CUSIP NO. 09609G100 13G Page 3 of 5 Pages

     

    Item 1.(a) Name of Issuer:

     

    bluebird bio, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    455 Grand Union Boulevard

    Somerville, Massachusetts 02145

     

    Item 2.(a) Name of Person Filing:

     

    Granahan Investment Management LLC

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    Wyman Street, Suite 460

    Waltham, MA 02451

     

    (c)Citizenship:

     

    State of Massachusetts

     

    (d)Title of Class of Securities:

     

    Common Stock, $0.01 par value per share

     

    (e)CUSIP Number:

     

    09609G100

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a)[  ] Broker or dealer registered under Section 15 of the Exchange Act.

     

    (b)[  ] Bank as defined in Section 3(a)(6) of the Exchange Act.

     

    (c)[  ] Insurance company as defined in Section 3(a)(19) of the Exchange Act.

     

    (d)[  ] Investment company registered under Section 8 of the Investment Company Act.

     

    (e[X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)[  ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)[  ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)[  ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i)[  ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    (j)[  ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

     

     

    CUSIP NO. 09609G100 13G Page 4 of 5 Pages

     

    Item 4.Ownership.

     

      (a) Amount beneficially owned: 0
      (b) Percent of class: 0.00%
      (c) Number of shares as to which the person has:  
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 0
        (iv) Shared power to dispose or to direct the disposition of: 0

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. [ ]

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    All of the Shares set forth in Item 4 are owned by various investment advisory clients of Granahan Investment Management LLC, which is deemed to be a beneficial owner of those shares pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, due to its discretionary power to make investment decisions over such shares and/or its ability to vote such shares.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable

     

     

    CUSIP NO. 09609G100 13G Page 5 of 5 Pages

     

    Item 10.Certification.

     

    By signing below the undersigned certifies that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Granahan Investment Management LLC  
           
      By:

    /s/Brian Granahan

     
      Name: Brian Granahan  
      Title: Chief Compliance Officer  
           
      Date: November 14, 2024  

     

     

     

    Get the next $BLUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLUE

    DatePrice TargetRatingAnalyst
    2/24/2025Underweight → Neutral
    Analyst
    2/24/2025$29.00Overweight
    Analyst
    11/18/2024Neutral → Underweight
    Analyst
    11/15/2024Neutral → Underweight
    JP Morgan
    11/15/2024$3.00 → $0.50Buy → Neutral
    BofA Securities
    8/15/2024Overweight → Neutral
    JP Morgan
    12/11/2023Hold → Reduce
    HSBC Securities
    12/8/2023$3.00 → $7.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

      New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers bluebird bio (NASDAQ:BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital"). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer

      6/2/25 8:34:00 AM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

      All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025 Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") for either (x) $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right ("CVR") if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December

      5/30/25 8:30:00 AM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital

      bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird" or "the Company") today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 29, 2025. Stockholders that hold shares of bluebird through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it is important to act now. Additionally, the Company today announced that Ayrmid Ltd. ("Ayrmid") has confirmed it will not submit a binding proposal to acquire bluebird following bluebird's amended agreement with Carlyle and SK Capital. The bluebird Board of Directors

      5/27/25 8:30:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

      For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

      12/8/23 11:12:21 AM ET
      $BLUE
      $VRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

      For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

      8/17/22 2:12:27 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business & Legal Officer Vittiglio Joseph returned 5,625 shares to the company and was granted 2,500 shares, closing all direct ownership in the company (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      6/3/25 6:02:16 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Agwunobi John O returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      6/3/25 5:46:09 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vachon Mark returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      6/3/25 5:38:38 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    SEC Filings

    See more
    • SEC Form 15-12G filed by bluebird bio Inc.

      15-12G - bluebird bio, Inc. (0001293971) (Filer)

      6/12/25 6:05:15 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by bluebird bio Inc.

      EFFECT - bluebird bio, Inc. (0001293971) (Filer)

      6/4/25 12:15:02 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by bluebird bio Inc.

      POS AM - bluebird bio, Inc. (0001293971) (Filer)

      6/2/25 10:37:46 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:39:36 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:27:32 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 10:32:08 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care